KynderMed, Inc. Begins an Important Clinical Study at Tampa General Hospital to Advance Light Therapy Technology Inhibiting Preterm Contractions in Pregnant Women
TALLAHASSEE, Fla., Sept. 11, 2018
TALLAHASSEE, Fla., Sept. 11, 2018 /PRNewswire-PRWeb/ -- KynderMed, Inc. is a Tallahassee Florida based innovative medical device company with proprietary technology regulating uterine contractions in pregnant women. The technology will improve clinical outcomes by reducing preterm contractions.
The USF Health Morsani College of Medicine at the University of South Florida, Tampa, and Tampa General Hospital have approved a clinical study that will advance KynderMed's patented use of specific light to inhibit preterm contractions. After three previous clinical trials demonstrating that light inhibits uterine contractions, this study is the first to use the KynderMed light therapy on women exclusively having preterm contractions. The study was funded by KynderMed with matching funds from the Florida High Tech Corridor Council.
Florida State University Medical College Professor James Olcese's chief contribution to science is the discovery that the nightly release of melatonin is a cause of contractions in pregnant women; thus, inhibiting melatonin with the KynderMed light emitting sleep mask will be sufficient to inhibit preterm contractions in pregnant women. The sleep mask emits a brief light through the sleeping woman's eyelids and creates a circadian signal which then acutely suppresses melatonin and, subsequently, contractions.
"For over 37 years, the issue of preterm labor has remained an innovation wasteland," said Marc Lawrence, KynderMed CEO. "KynderMed's effective, yet simple, light therapy will have a revolutionary impact on the health of babies by inhibiting preterm contractions and reducing the effects of early labor."
The study's principal Investigator Judette Louis, MD MPH, Division Director of Maternal and Fetal Medicine at USF Health Morsani College of Medicine said: "Preterm birth remains a significant cause of death and chronic illness in children but few interventions have made a difference. The KynderMed light therapy is a groundbreaking effort to combine what we know about technology and the physiology of preterm in order to improve outcomes."
About Preterm Birth
Every year, about 15 million babies are born prematurely globally – with 1 Million babies dying as a result. All newborns are vulnerable, but preterm babies are acutely so. Many require critical care simply to remain alive. Prematurity is the world's single biggest cause of newborn death, and the second leading cause of all child deaths, after pneumonia. Many of the preterm babies who survive face a lifetime of disability.
About KynderMed's Approach
KynderMed is employing novel proprietary technology developed by Dr. James Olcese, Professor of Biomedical Sciences, Neuroscience and Molecular Biophysics at Florida State University's College of Medicine.
The prospect of moving this technology to the women who so desperately need a safe and effective means to inhibit preterm contractions and improve outcomes creates a tremendous passion and energy among our team.
KynderMed is being advised by the newportboardgroup.com [Newport Board Group __title__ Newport Board Group].
Melanie Simmons, PhD
President & Chief Development Officer
M: (850) 322-4629
Newport Board Group, LLC
SOURCE Newport Board Group, LLC